- Home
- / Carisma Therapeutics
Carisma Therapeutics
Stock Price
$1
2024-10-29
Market Capitalization
$42 M
2024-10-29
Revenue
$19.6 M
FY, 2024
Carisma Therapeutics Summary
Company Summary
- Overview
- Carisma Therapeutics (formerly known as CARMA Therapeutics) is a pre-clinical stage biotechnology company that develops cellular therapeutics. It offers CAR-Macrophages and CAR-Monocytes cell therapy platforms focused on engineered macrophages to transform the treatment of cancer and other illnesses.
- Type
- Public
- Status
- Active
- Founded
- 2008
- HQ
- Philadelphia, PA, US | view all locations
- Website
- https://carismatx.com/
- Cybersecurity rating
Table of Contents
Key People
Daniel Cushing, Chief Technology and Development Officer
Sascha Abramson, Vice President, Scientific Operations
Michael Klichinsky, Co-Founder and Chief Scientific Officer
LocationsView all
1 location detected
Philadelphia, PA HQ
United States
3675 Market St #401
Carisma Therapeutics Financials
Summary Financials
- Revenue (Q3, 2025)
- $45.3M
- Net income (Q3, 2025)
- $44.7M
- Cash (Q3, 2025)
- $2.8M
- EBIT (Q3, 2025)
- $43.8M
- Enterprise value
- $39.9M